Noopept

Noopept is not a racetam by structure. It was designed at the Zakusov Institute in Moscow by taking the Piracetam pharmacophore and rebuilding it as a short peptide — the ethyl ester of N-phenylacetyl-L-prolylglycine [1]. It is filed with the racetams here because that is its lineage and how it is sold; its cognitive-peptide character is closer to Semax and Selank.

Its developers report that it exceeds piracetam both in effective dose — about a thousand times lower — and in the breadth of its effect on memory: where piracetam facilitates only the early stages, noopept is reported to act on consolidation and retrieval as well, with an additional selective anxiolytic action [1]. It is registered and prescribed in Russia for cognitive deficits of cerebrovascular and post-traumatic origin [1].

Two findings dominate.

The first is that noopept is a prodrug. An hour after 5 mg/kg intraperitoneally, noopept itself could not be detected in rat brain at all. What had risen — 2.5-fold — was cycloprolylglycine, a cyclic dipeptide the brain already produces endogenously and which has nootropic activity of its own. The conversion also happens in vitro in the presence of plasma and brain enzymes [2]. Later pharmacokinetic work confirmed that cycloprolylglycine differs markedly from the parent in its kinetics while sharing its pharmacological spectrum [5]. One caveat: an oral study found noopept stimulated one-session learning in a way its metabolite and piracetam did not, so the prodrug story may not be the whole of it [6].

The second is HIF-1. When noopept was screened against nine transcription factors in transfected HEK293 cells, it increased the DNA-binding activity of hypoxia-inducible factor 1 and of nothing else — not CREB, NFAT, NF-κB, p53, STAT1, GAS, VDR or HSF1. The effect was concentration-dependent and additive with chemically induced HIF-1 stabilisation, and molecular docking suggested that noopept and its active L-isomer metabolite bind the active site of prolyl hydroxylase 2, the enzyme that marks HIF-1α for destruction. Piracetam at a hundred times the concentration affected none of the nine [4].

Downstream, noopept raises NGF and BDNF mRNA in rat hippocampus after a single dose, and 28 days of dosing potentiated rather than blunted the effect [7]. In cell models it reduced oxidative damage and apoptosis in human cortical neurons, including Down syndrome neurons [8], and reduced apoptosis and tau hyperphosphorylation in an Alzheimer's model [9]. In a rat photochemical stroke model it restored memory and protected tissue [10].

No controlled human safety data is cited here. The 60-patient open study of 20 mg daily for two months in stroke patients reported a high level of safety, but it had no blinded comparator and was not designed to detect harm [3].

The concrete risk is dosing. Noopept is active in milligrams where the rest of the class is active in grams, so the margin for error in an unregulated product is small. In a 2021 analysis of cognitive-enhancement supplements, the maximum omberacetam exposure from a recommended serving was 40.6 ± 0.4 mg against a typical pharmacologic dose of 10 mg — a fourfold overshoot — and products in that category routinely contained undeclared unapproved drugs such as phenibut, vinpocetine and picamilon, with 75% of declared quantities inaccurate [12].

European medicines control laboratories intercepted noopept as bulk raw material during a 2020–2024 market surveillance exercise, alongside phenylpiracetam and phenibut, noting that consumers buying these as dietary supplements may not be aware of the risks [14].